

## Redeye Initiates Coverage of WntResearch

Redeye initiates coverage of WntResearch, a Swedish biotechnology company specialised in oncology. Its phase II drug candidate, Foxy-5, focuses on colon cancer and intends to decrease tumors and reduce cancer spread. Our fair value range suggests a significant upside potential in the share, and we argue that upcoming interim data and a potential licensing deal are two major catalysts in the short term.

[Read more and download the Research Report.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Redeye Initiates Coverage of WntResearch](#)